IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

| HOSPIRA, INC. |) |
|-------------------------|-----------------------------------|
| |) |
| Plaintiff, |) |
| |) C.A. No. 16-cv-651 |
| v. |) C.A. No. 17-cv-7903 |
| |) |
| FRESENIUS KABI USA, LLC |) Hon. Judge Rebecca R. Pallmeyer |
| |) |
| Defendant. |) |

JOINT MOTION TO ENTER STIPULATION

Plaintiff Hospira, Inc. and Defendant Fresenius Kabi USA, LLC ("the parties") respectfully request that the Court enter the attached Joint Stipulation regarding infringement and modifications to the case schedule. In support of this Motion, the parties state:

- 1. On January 4, 2018, the Court entered a Revised Scheduling Order that set deadlines for, among other things, Fresenius Kabi's invalidity contentions, Hospira's responses thereto, expert discovery, and a final pre-trial order. (Case No. 17-7903, D.I. 23.)
- 2. On January 5, 2018, Fresenius Kabi served its Amended Final Invalidity Contentions.
- 3. On January 16, 2018, following discussions with Fresenius Kabi about Hospira's objections to the contentions, Hospira moved to strike certain theories raised in Fresenius Kabi's Amended Final Contentions. (D.I. 81.) In the alternative, Hospira requested that the case schedule be extended to allow Hospira time to investigate those theories.
- 4. As discussed at the January 25, 2018, status hearing, the parties have reached an agreement to resolve the dispute set forth in Hospira's Motion to Strike. The details of the parties' agreement is set forth in the attached Joint Stipulation.



WHEREFORE, the parties request that the Court enter the Stipulation attached as Exhibit

A.

Dated: January 26, 2018

Respectfully submitted,

/s/ Bradford P. Lyerla

Bradford P. Lyerla
Sara T. Horton
Yusuf Esat
Ren-How Harn
JENNER & BLOCK LLP
353 N. Clark Street
Chicago, IL 60654-3456
(312) 222-9350
blyerla@jenner.com
shorton@jenner.com
yesat@jenner.com
rharn@jenner.com

Attorneys for Plaintiff Hospira, Inc.

/s/ Joel M. Wallace

Imron T. Aly
Joel M. Wallace
Emily M. Peña
Tara L. Feld
233 South Wacker Drive, Suite 7200
Chicago, Illinois 60606
(312) 258-5500
ialy@schiffhardin.com
jwallace@schiffhardin.com
epena@schiffhardin.com
tkurtis@schiffhardin.com

Ahmed M.T. Riaz (*pro hac vice*) 666 Fifth Avenue, 17th Floor New York, NY 10103 (212) 753-5000 ariaz@schiffhardin.com

Attorneys for Defendant Fresenius Kabi USA, LLC



CERTIFICATE OF SERVICE

I, Yusuf Esat, an attorney at the law firm of Jenner & Block LLP, hereby certify that on January 26, 2018, I caused a true and correct copy of the foregoing **JOINT MOTION TO**ENTER STIPULATION to be electronically served on counsel of record via the Court's CM/ECF system.

| /s/ Yusuf Esat | |
|----------------|--|
| Yusuf Esat | |



Exhibit A

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

| HOSPIRA, INC. |) |
|-------------------------|-----------------------------------|
| |) |
| Plaintiff, |) |
| |) C.A. No. 16-cv-651 |
| v. |) C.A. No. 17-cv-7903 |
| |) |
| FRESENIUS KABI USA, LLC |) Hon. Judge Rebecca R. Pallmeyer |
| |) |
| Defendant. |) |

[PROPOSED] JOINT STIPULATION

This stipulation is made by and between Plaintiff Hospira, Inc. ("Hospira") and Defendant Fresenius Kabi USA, LLC ("Fresenius Kabi").

WHEREAS, on January 15, 2016, Hospira filed a Complaint against Fresenius Kabi for infringement of U.S. Patent Nos. 8,242,158; 8,338,470; 8,455,527; and 8,648,106, captioned *Hospira, Inc. v. Fresenius Kabi USA, LLC*, C.A. No. 16-cv-651 ("the First Action"), related to Fresenius Kabi's submission of Amended New Drug Application No. 208129 ("ANDA 208129") to the Food and Drug Administration seeking approval to market dexmedetomidine hydrochloride for injection, 80 mcg/20 mL, 200 mcg/50 mL, and 400 mcg/100 mL ("Fresenius Kabi's Proposed ANDA Products");

WHEREAS, on November 1, 2017, Hospira filed a Complaint against Fresenius Kabi for infringement of later-issued U.S. Patent No. 9,616,049, captioned *Hospira, Inc. v. Fresenius Kabi USA, LLC*, C.A. No. 17-cv-7903 ("the Second Action"), related to Fresenius Kabi's submission of ANDA 208129 to the Food and Drug Administration seeking approval to market Fresenius Kabi's Proposed ANDA Products;



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

